Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen
- Address
- lock Available on a paid plan
Neoplasms
At Queen Silvia Children’s Hospital researchers are testing novel anti‑cancer agents and combination regimens to increase cure rates while limiting long‑term side effects in children with solid and hematologic malignancies.
- Acute Lymphoblastic Leukaemia
- Acute Myeloid Leukaemia
- Brain Tumor
- Medulloblastoma
- Neuroblastoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Lymphomas (Hodgkin and non‑Hodgkin)
- Atypical Teratoid/Rhabdoid Tumour
The site hosts 44 active trials with 68 investigators, many of which are multinational collaborations focused on improving event‑free survival and quality of life.
Hemic and Lymphatic Diseases
Studies here assess blood‑forming disorders and lymphoid cancers, seeking more effective and less toxic treatment options for young patients.
- Acute Lymphoblastic Leukaemia
- Acute Myeloid Leukaemia
- Chronic Graft‑Versus‑Host Disease
- Anemia associated with Chronic Kidney Disease
- Lymphoblastic Lymphoma
- Anaplastic Large Cell Lymphoma (ALCL)
Research aims to boost remission rates and reduce relapse by integrating targeted agents and immunotherapies into standard chemotherapy backbones.
Immune System Diseases
The department investigates disorders driven by immune dysregulation, evaluating both disease‑modifying drugs and supportive therapies.
- Chronic Graft‑Versus‑Host Disease
- Proteinuric Glomerular Diseases (FSGS, IgAN, MCD, IgAV, Alport Syndrome)
- Inflammatory Myofibroblastic Tumor
- C3 Glomerulopathy
Trials often compare novel complement inhibitors or renin blockers with established ACE inhibitors to protect kidney function.
Digestive System Diseases
Researchers focus on improving nutrition and intestinal health in vulnerable pediatric populations, testing therapies that enhance gut absorption.
- Intestinal Malabsorption in Preterm Infants
- Ulcerative Colitis
The goal is to shorten time to full enteral feeding and achieve sustained remission with fewer steroids.
Congenital, Hereditary, and Neonatal Diseases
Efforts target rare genetic conditions, aiming to modify disease progression and improve functional outcomes from early childhood.
- Congenital Myopathy
- Dravet Syndrome
- Mucopolysaccharidosis Type II (Hunter Syndrome)
- Niemann‑Pick Type C Disease
- GM1/GM2 Gangliosidoses
Studies include gene‑transfer approaches, enzyme replacement, and small‑molecule therapies designed to cross the blood‑brain barrier.
Musculoskeletal Diseases
Clinical work seeks to restore muscle strength and mobility in children affected by inherited muscular disorders and tumor‑related muscle disease.
- Duchenne Muscular Dystrophy
- Congenital Myopathy
- Rhabdomyosarcoma
Trials evaluate exon‑skipping agents, micro‑dystrophin gene therapy, and novel chemoradiation schedules to preserve limb function.
Nervous System Diseases
The center conducts research on brain and spinal cord disorders, testing interventions that protect cognition and reduce tumor‑related damage.
- Brain Tumor
- Medulloblastoma
- Dravet Syndrome
- Atypical Teratoid/Rhabdoid Tumour
Projects include lithium neuroprotection after radiotherapy and precision‑medicine trials using targeted inhibitors for rare CNS tumors.
Pathological Conditions, Signs and Symptoms
Investigations address acute clinical complications and symptom‑focused outcomes, striving to improve recovery speed and quality of life.
- Acute Kidney Injury after Cardiac Surgery
- Facial Nerve Palsy (Bell’s Palsy)
- Proteinuric Glomerular Diseases
Therapeutic strategies such as peptide hormones and anti‑inflammatory agents are being compared with standard care to reduce organ injury.
Behavioral and Psychological Research
Studies explore neuropsychiatric syndromes and immune response after cancer treatment, aiming to restore mental health and vaccine efficacy.
- Pediatric Acute‑Onset Neuropsychiatric Syndrome (PANS)
- Immunity after Revaccination (Varicella, Measles)
- Cognitive Processing Speed after Brain Radiotherapy
Outcomes focus on symptom severity scales, antibody titers, and neurocognitive testing to guide supportive interventions.
Therapeutic Techniques and Equipment
The site evaluates cutting‑edge diagnostic tools and delivery systems to enhance precision of pediatric therapies.
- Anti‑angiogenic Treatment Response Monitoring
- Advanced Imaging for Tumor Volume Assessment
- Pharmacokinetic Modeling of Targeted Agents
By integrating real‑time imaging and biomarker analytics, trials aim to tailor dosing and reduce unnecessary exposure.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 29 therapeutic areas and 15 of 505 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 472 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 101 by active trials.
- 1Vaestra Goetalandsregionen22active
lock +100 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vaestra Goetalandsregionen34trials
lock +51 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen
lock Showing 1 of 331 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized Controlled Trial Comparing Dapagliflozin Propanediol and Metformin in Early Stage Type 2 Diabetes for Mortality and Vascular Complications | Uppsala University | Phase III | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 505 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 19 | Unknown | 2013-10-18 | 2025-12-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.